Biotech merger wave gathers up KS Bio

- Last updated on GMT

Related tags: Biotechnology, Biogen idec

KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.

UK biopharmaceutical company KS Biomedix has confirmed that it is in negotiations that may lead to a merger and add to the mini-wave of consolidation sweeping over the UK industry.

The company, which combines cancer drug discovery and development with a contract biologics manufacturing system (KS Avicenna), confirmed that talks were ongoing in a statement released yesterday.

The company's shares rose on speculative activity ahead of its confirmation, but dropped back after it emerged that the proposed deal was for a price per share below KS Biomedix' prevailing level of 17.75 pence. By the close of trading, the shares had dropped by a penny to 14 pence, but recouped this decline in early trading today.

There has been increasing M&A activity on both sides of the Atlantic in the last few weeks, with British Biotech hooking up with Vernalis and Celltech buying Oxford Glycosciences in the UK, and Biogen announcing a proposed merger with IDEC Pharmaceuticals in the US. Meanwhile, two deals have been struck between US and European firms - Chiron/PowderJect and Cell Therapeutics/Novuspharma.

This trend for consolidation follows a difficult 2002 for the European biotechnology sector. After a decade of 30-40 per cent year-on-year growth in revenues and 10-20 per cent increases in employee numbers, the sector stalled in 2002, with revenues falling 2 per cent to €12.9 billion and employee numbers declining 6 per cent to 82,100, according to Ernst & Young.

Related news

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars